As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…
AWS announced a wave of new AI agent tools at re:Invent 2025, but can Amazon actually catch up to the AI leaders? While the cloud giant is betting big on enterprise AI with its third-gen chip and database discounts that got developers cheering, it’s still fighting to prove it can compete beyond infrastructure. This week […]